AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents
Completed
- Conditions
- Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies)Healthy Subjects (Treated With no Diabetes Therapies)
- Interventions
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 363766
- Registration Number
- NCT01077323
- Locations
- 🇺🇸
Research Site, Waltham, Massachusetts, United States
Study of Undertreatment of Patients With Dyslipidemia in Bulgaria
Completed
- Conditions
- Dyslipidemia
- First Posted Date
- 2010-02-25
- Last Posted Date
- 2010-09-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2500
- Registration Number
- NCT01075594
- Locations
- 🇧🇬
Research Site, Veliko Turnovo, Bulgaria
Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- Drug: ZD9393 (Zoladex) 10.8 mgDrug: ZD9393 (Zoladex) 3.6 mg
- First Posted Date
- 2010-02-23
- Last Posted Date
- 2018-12-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 222
- Registration Number
- NCT01073865
- Locations
- 🇹🇭
Research Site, Ubonratchathani, Thailand
A Study to to Assess the Effect of Dapagliflozin When Administered Once a Day Versus Twice a Day on Blood Glucose
- First Posted Date
- 2010-02-22
- Last Posted Date
- 2012-06-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT01072578
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Study to Assess MEDI -578 in Patients With Osteoarthritis (OA) of the Knee
- First Posted Date
- 2010-02-22
- Last Posted Date
- 2013-01-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 108
- Registration Number
- NCT01072591
- Locations
- 🇬🇧
Research Site, London Bridge, Greater London, United Kingdom
A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2010-02-18
- Last Posted Date
- 2014-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 328
- Registration Number
- NCT01070784
- Locations
- 🇯🇵
Research Site, Kyoto, Japan
A Study in Healthy Volunteers to Assess Effect of AZD6765 on Midazolam Blood Levels
- First Posted Date
- 2010-02-17
- Last Posted Date
- 2014-10-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 46
- Registration Number
- NCT01069822
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Comparative Efficacy & Safety Study of D961H Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With Low-dose Aspirin
- First Posted Date
- 2010-02-17
- Last Posted Date
- 2012-11-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 427
- Registration Number
- NCT01069939
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Budesonide/formoterol (Symbicort Turbuhaler)
- First Posted Date
- 2010-02-17
- Last Posted Date
- 2012-10-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1293
- Registration Number
- NCT01069289
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
🇵🇭Researche Site, San Fernando, Pampanga, Philippines
To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients
Phase 1
Completed
- Conditions
- Glucose Lowering
- First Posted Date
- 2010-02-17
- Last Posted Date
- 2010-12-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 21
- Registration Number
- NCT01069926
- Locations
- 🇺🇸
Research Site, Knoxville, Tennessee, United States